Simultaneous use of thyrotropin-releasing hormone test and combined dexamethasone/corticotropine-releasing hormone test for severity evaluation and outcome prediction in patients with major depressive disorder

Isogawa, Koichi; Nagayama, Haruo; Tsutsumi, Takashi; Kiyota, Akio; Akiyoshi, Jotaro; Hieda, Keiko

doi:10.1016/j.jpsychires.2004.11.003

Cited by 15 publications

(8 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…MDD patients showed visible HPA axis abnormality (47), CRF in CSF was higher than in control subjects (48), and amygdala hyperactivity was reported (49). Weniger et al (50) reported that MDD patients were significantly impaired in learning fearful emotional facial expression and larger left amygdala volumes were significantly related to worse memory performance and to higher anxiety score of MDD patients.…”

Section: Discussionmentioning

confidence: 99%

Contrasting Effects of Pretraining, Posttraining, and Pretesting Infusions of Corticotropin-Releasing Factor into the Lateral Amygdala: Attenuation of Fear Memory Formation but Facilitation of its Expression

Isogawa

Bush

LeDoux

2013

Biological Psychiatry

View full text Add to dashboard Cite

Background The lateral nucleus of the amygdala (LA) is a crucial part of the neural circuitry underlying the formation and storage of memories established through fear conditioning. To investigate corticotropin-releasing factor (CRF) contributions to fear memory in LA, the present experiments tested the effects of intra-LA infusions on the formation and expression of memory after Pavlovian fear conditioning. Methods In experiment 1, CRF was infused bilaterally into LA of rats one hour before fear conditioning training. Two days later, rats were tested for conditioned stimulus (CS)-elicited freezing behavior in a distinct context. In experiment 2 rats were infused with CRF in LA immediately after auditory fear conditioning and then tested two days later. In experiment 3 rats were fear conditioned, and then two days later infused with CRF in LA one hour before fear memory testing to assess effects on the expression of fear memory. Finally, we repeated the pre-training and pre-testing experiments with the central nucleus of the amygdala (CE) infusions. Results Rats given either pre- or post-training CRF infusions in LA showed dose-dependent suppression of CS-elicited freezing in the fear memory test session. In contrast, rats given pre-testing CRF showed facilitation of CS-elicited freezing. CRF infusions into the CE had no effect when given before training or testing. Conclusions CRF infusions into LA impair the consolidation of memory for fear conditioning, but enhance the expression of pre-established fear memories. These findings may have important implications for understanding mechanisms underlying contributions of CRF to fear-related disorders.

show abstract

Section: Discussionmentioning

confidence: 99%

Contrasting Effects of Pretraining, Posttraining, and Pretesting Infusions of Corticotropin-Releasing Factor into the Lateral Amygdala: Attenuation of Fear Memory Formation but Facilitation of its Expression

Isogawa

Bush

LeDoux

2013

Biological Psychiatry

View full text Add to dashboard Cite

show abstract

“…49,50 It correlates with biological markers of depression. [51][52][53][54][55] However, somatic symptoms are heavily represented, 56 and its use as a screening measure, particularly in patients with physical illness, has been criticized. 56,57 Thus, almost 60% of the total items could be experienced by a typical patient with PD.…”

Section: Depression In Non-pd Patientsmentioning

confidence: 99%

Depression rating scales in Parkinson's disease: Critique and recommendations

Schrag¹,

Barone²,

Brown³

et al. 2007

Movement Disorders

594

348

View full text Add to dashboard Cite

Depression is a common comorbid condition in Parkinson's disease (PD) and a major contributor to poor quality of life and disability. However, depression can be difficult to assess in patients with PD due to overlapping symptoms and difficulties in the assessment of depression in cognitively impaired patients. As several rating scales have been used to assess depression in PD (dPD), the Movement Disorder Society commissioned a task force to assess their clinimetric properties and make clinical recommendations regarding their use. A systematic literature review was conducted to explore the use of depression scales in PD and determine which scales should be selected for this review. The scales reviewed were the Beck Depression Inventory (BDI), Hamilton Depression Scale (Ham-D), Hospital Anxiety and Depression Scale (HADS), Zung Self-Rating Depression Scale (SDS), Geriatric Depression Scale (GDS), Montgomery-Asberg Depression Rating Scale (MADRS), Unified Parkinson's Disease Rating Scale (UPDRS) Part I, Cornell Scale for the Assessment of Depression in Dementia (CSDD), and the Center for Epidemiologic Studies Depression Scale (CES-D). Seven clinical researchers with clinical and research experience in the assessment of dPD were assigned to review the scales using a structured format. The most appropriate scale is dependent on the clinical or research goal. However, observer-rated scales are preferred if the study or clinical situation permits. For screening purposes, the HAM-D, BDI, HADS, MADRS, and GDS are valid in dPD. The CES-D and CSDD are alternative instruments that need validation in dPD. For measurement of severity of depressive symptoms, the Ham-D, MADRS, BDI, and SDS scales are recommended. Further studies are needed to validate the CSDD, which could be particularly useful for the assessment of severity of dPD in patients with comorbid dementia. To account for overlapping motor and nonmotor symptoms of depression, adjusted instrument cutoff scores may be needed for dPD, and scales to assess severity of motor symptoms (e.g., UPDRS) should also be included to help adjust for confounding factors. The HADS and the GDS include limited motor symptom assessment and may, therefore, be most useful in rating depression severity across a range of PD severity; however, these scales appear insensitive in severe depression. The complex and time-consuming task of developing a new scale to measure depression specifically for patients with PD is currently not warranted.

show abstract

“…Isogawa et al [46] have recently reported that all of the unimproved patients were located in the region representing a value of ! 3 for the ⌬ MAX ACTH/ ⌬ MAX TSH at the time of admission.…”

Section: Discussionmentioning

confidence: 99%

“…Additionally, there is a lack of nondepressed controls in our study. Some studies have showed mixed results on the effect of stress on the DST status of healthy subjects [46,47,48] , and Oshima et al [49] reported that acute stressors did not show a significant response in the DEX/CRH test. Additional limitation is that all patients received medication and some received nonconvulsive EST administration, which may have influenced the results of the TRH and DEX/CRH tests.…”

Section: Discussionmentioning

confidence: 99%

Enhanced Suppression of Adrenocorticotropic Hormone and Cortisol Responses to Hypothalamic-Pituitary-Adrenal Function and Thyrotropin-Releasing Hormone Tests after Stressful Life Events in Patients with Major Depressive Disorder

Hikichi

Akiyoshi²,

Ichioka³

et al. 2007

Neuropsychobiology

View full text Add to dashboard Cite

Background: It is commonly believed that there exists a relationship between the outcome of thyrotropin-releasing hormone (TRH) test, the combined dexamethasone/corticotropin-releasing hormone (DEX/CRH) test and stressful life events (SLEs) in major depressive disorder. Objective: SLEs influence the TRH and DEX/CRH tests in major depressive disorder when administered at the time of admission and improvement. Methods: The TRH and DEX/CRH tests were administered to patients hospitalized for major depressive disorders – on the 4th through the 7th hospital day and at the time of improvement. We measured ΔMAX TSH, ΔMAX ACTH, ACTH AUC, ΔMAX cortisol, cortisol AUC, ΔMAX ACTH/ΔMAX TSH and ΔMAX cortisol/ΔMAX TSH. Results: SLEs were significantly negatively associated with ΔMAX ACTH, ACTH AUC and cortisol AUC at the time of admission. However, these relationships lost significance at the time of improvement. The sample (41 patients at the time of admission, 18 patients at the time of improvement) was relatively small, which may have contributed to false-negative results. Conclusion: SLEs may be negatively associated with the outcome of the DEX/CRH tests in major depressive disorder. The hypothalamic-pituitary-adrenal axis in the DEX/CRH test was modulated by SLEs.

show abstract

Simultaneous use of thyrotropin-releasing hormone test and combined dexamethasone/corticotropine-releasing hormone test for severity evaluation and outcome prediction in patients with major depressive disorder

Cited by 15 publications

References 19 publications

Contrasting Effects of Pretraining, Posttraining, and Pretesting Infusions of Corticotropin-Releasing Factor into the Lateral Amygdala: Attenuation of Fear Memory Formation but Facilitation of its Expression

Contrasting Effects of Pretraining, Posttraining, and Pretesting Infusions of Corticotropin-Releasing Factor into the Lateral Amygdala: Attenuation of Fear Memory Formation but Facilitation of its Expression

Depression rating scales in Parkinson's disease: Critique and recommendations

Enhanced Suppression of Adrenocorticotropic Hormone and Cortisol Responses to Hypothalamic-Pituitary-Adrenal Function and Thyrotropin-Releasing Hormone Tests after Stressful Life Events in Patients with Major Depressive Disorder

Contact Info

Product

Resources

About